NASDAQ · XOMAP

XOMA Royalty Corporation 8. 625% Cumulative Perpetual

$24.98 +$0.01 (+0.04%) 1D
Charting by TradingView

Key Metrics

$444.17M
Market cap
13.14×
P/E · TTM
$48.56M
Revenue · TTM
$33.81M
Net income
EPS · TTM $1.90
Dividend yield 1.2%
Free cash flow —
Beta · 1Y 0.11
EBITDA · TTM —
Gross margin —

Snapshot

Market cap—
Enterprise value$461.41M
Shares outstanding—
52-wk range$24.93 – $30.00
Avg volume · 20D2.8K
Net cash −$17.24M
Book value / share$5.22
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About XOMA Royalty Corporation 8. 625% Cumulative Perpetual
IPO dateDec 16, 2020
Employees14

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E13.14
P/S9.15
P/FCF—
EV/EBITDA—
EV/Sales9.50
Graham №$14.95

Profitability

Gross —
Operating 62.5%
Net 69.6%
FCF —
ROE / ROIC 38.7% · —

Financial Health

Current ratio3.59
Quick ratio—
Debt / equity1.11
Debt / EBITDA —
Net cash −$17.24M
Working capital$85.67M

Cash Flow · TTM

Operating CF $6.79M
Capex —
Free cash flow —
Buybacks $15.76M
Dividends paid $5.53M
Shareholder yield 4.8%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

-3.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$14.95 vs $24.98
Trades 1.7× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings